BPBrendan Nicholas Putko

Brendan Nicholas Putko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brendan Nicholas Putko has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neuromuscular Ultrasound and Electrophysiologic Correlation of Median Mononeuropathy at the Wrist in Symptomatic Hereditary Transthyretin Amyloidosis

    by Kira S. Kopacz, Marcus V. Pinto, Andrea J. Boon, Marianne T. Luetmer, Ruple S. Laughlin, Brendan Putko, William J. Litchy, Michelle L. Mauermann, James B. Meiling

    Purpose: Hereditary transthyretin amyloidosis (ATTRv) is a progressive multisystem disease in which median mononeuropathy at the wrist (MNW) is common and often precedes systemic involvement. Nerve conduction studies (NCS) have historically been the gold standard for MNW, but neuromuscular ultrasound (NMUS) is complementary. The aim of this study was to compare NMUS with electrodiagnostic (EDX) testing for the diagnosis of MNW in patients with symptomatic ATTRv. Methods: A retrospective review was performed of patients 18 years and older with ATTRv confirmed by genetic testing who underwent both EDX testing and NMUS of the median nerve between 2019 and 2025. Demographic, NMUS, and EDX data were collected. Results: Data from 15 upper limbs in 10 patients were analyzed. Median nerve cross‐sectional area at the wrist was significantly greater than reference values ( P = 0.041). MNW was identified in 80% of wrists by NMUS and 100% by NCS, with no significant difference between modalities. Median nerve cross‐sectional area at the wrist did not significantly correlate with MNW severity determined by NCS ( r = −0.018; P = 0.941) or with any NCS parameters (all P > 0.080). Concurrent polyneuropathy was diagnosed in 60% of patients, but there was no association between polyneuropathy and MNW detection by either modality ( P > 0.197). Conclusions: NMUS and NCS demonstrate comparable diagnostic accuracy for MNW in ATTRv. Given its noninvasive nature and efficiency, NMUS may serve as an adjunct to classic EDX testing in this population.

  • Tocilizumab for severe immune checkpoint inhibitor myopathy–myocarditis: acute and long-term outcomes

    by Gurpreet Chaggar, Bridget Mulvany-Robbins, Matthew Anaka, Brendan Putko, Grayson Beecher

    Background Immune checkpoint inhibitor (ICI)-myopathy–myocarditis is an immune-related adverse event, with high mortality despite first-line immunosuppression. Emerging data suggest upregulation of the interleukin-6 (IL-6) pathway in ICI-myopathy, raising interest in IL-6 receptor blockade as escalation therapy. We aimed to characterize acute and long-term functional and oncologic outcomes for severe ICI-myopathy–myocarditis, with focus on those treated with tocilizumab after failure of first-line therapy. Methods We performed a retrospective cohort study of patients admitted with severe (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or 4) ICI-myopathy–myocarditis managed at a Canadian tertiary referral center. Clinical characteristics, investigations, treatment, and functional and long-term cancer outcomes were summarized. Patients were stratified by treatment with tocilizumab after first-line therapy. Primary outcomes were in-hospital mortality and acute-phase survival. Secondary outcomes included functional status at last follow-up, final CTCAE grade, and oncologic response. Results Eleven patients were identified. Eight patients received second-line tocilizumab at a median of 13 days after admission; weakness improved in all, but only 4 survived hospitalization. Among acute-phase survivors, median follow-up was 8.1 months, with final median CTCAE grade of 1. Limb strength normalized before oculobulbar weakness. Most survivors demonstrated partial oncologic response, followed by later disease progression at a median 8 months. No patients were rechallenged with ICI therapy. Discussion In severe ICI-myopathy–myocarditis refractory to first-line therapy, escalation with IL-6 receptor blockade was temporally associated with limb muscle strength improvement and favorable long-term functional outcomes among survivors. These findings support further evaluation of tocilizumab as second-line therapy in this high-risk population.

  • Medical Assistance in Dying in ALS

    by Ryan Hanjie Zhu, Sanjay Kalra, Peter Dobrowolski, Daniel Fok, Michèle DuVal, Brendan Nicholas Putko, Wendy Johnston, Grayson Beecher

    Medical assistance in dying (MAiD) has been available across Canada since 2016 for patients with amyotrophic lateral sclerosis (ALS). We aimed to characterize MAiD use, identify associated factors, and compare survival and location of death in a Canadian ALS cohort. We retrospectively reviewed patients with ALS followed at a Canadian multidisciplinary clinic who died between January 1, 2019 and December 31, 2024. Patient characteristics were described by MAiD status. Factors associated with MAiD utilization were evaluated using regression analyses, and survival and location of death were compared between patients who did and did not pursue MAiD. Of 255 patients (median age 67 years [IQR 60-75]; 42% female), 55 (21.6%) underwent MAiD. Percutaneous endoscopic gastrostomy (PEG) use was inversely associated with MAiD utilization (OR 0.34, 95% CI 0.15-0.78), whereas demographic and disease characteristics were not associated with MAiD. Survival from diagnosis to death was shorter among patients who underwent MAiD (median 12 vs 14 months; p = 0.019), with no difference from symptom onset. Death at home was more frequent with MAiD (62% vs 35%; p < 0.001). MAiD is a common end-of-life option in ALS, reflecting patient values and is associated with lower PEG use, shorter postdiagnosis survival, and more frequent death at home.


  • Open Access

    Expanding the Molecular and Pathologic Spectrum of HSPB8 Myopathy and Distal Motor Neuropathy

    by Brendan Nicholas Putko, Eric J. Sorenson, Gaofeng Cui, Teerin Liewluck, Zhiyv Niu, William J. Litchy, Georges Mer, Margherita Milone

    HSPB8 variants cause myopathy, distal motor neuropathy, and Charcot-Marie-Tooth disease. We describe 2 patients who expand the molecular and pathologic spectrum of HSPB8 disorder. We reviewed clinical and laboratory data and performed molecular dynamics simulations to explore variant effect. Patient 1 is an adult man presenting with childhood-onset, distal lower limb weakness, followed by proximal weakness. EMG detected predominant myopathic and neurogenic changes in upper and lower limbs, respectively. Biopsy revealed myopathy with rimmed vacuoles in the supraspinatus and neurogenic changes in the tibialis anterior. He carries a novel, predicted deleterious HSPB8 heterozygous variant, c.185G>A (p. Gly62Asp). Patient 2 is an adult man presenting with distal, asymmetric, progressive lower limb weakness that extended to proximal and neck muscles. Quadriceps biopsy showed myopathy with rimmed vacuoles and protein aggregates, especially TIA1, p62, and TDP-43. TIA1 aggregates were more prominent than Z-disk protein accumulation. He carries a known HSPB8 pathogenic variant, c.421 A>G (p.Lys141Glu). Molecular dynamics simulations suggested that p.Gly62Asp may exert its effects through post-translation modifications while p.Lys141Glu may disrupt dimerization. HSPB8 p.Gly62Asp is the first N-terminal variant associated with myopathy. TIA1 aggregates, more prominent than Z-disk myofibril aggregates, suggest that p.Lys141Glu may affect stress granule dynamics more than Z-disk integrity.


  • Statins in Genetic Myopathies

    by Brendan Nicholas Putko, Margherita Milone, Teerin Liewluck

    Statins are widely prescribed lipid-lowering agents, but their safety and tolerability in patients with underlying genetic myopathies remain uncertain. We aimed to study statin safety and tolerability in genetic myopathies using a large retrospective cohort. We conducted a retrospective study in patients with myotonic dystrophy type 1 (DM1) and type 2 (DM2), facioscapulohumeral dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), and metabolic or mitochondrial myopathies who were exposed to statins. We included 135 patients (36 with DM1, 46 with DM2, 22 with FSHD, 6 with LGMD, 17 with mitochondrial myopathy, 6 with glycogenosis, and 2 with disorders of fatty acid oxidation or carnitine transport). A total of 44 patients discontinued statins, most often for statin-associated muscle symptoms (SAMS; n = 20). SAMS occurred in 36 of 135 patients (26.67%; 8 with DM1, 10 with DM2, 7 with FSHD, 3 with LGMD, 4 with mitochondrial myopathy, and 4 with metabolic myopathy). Myalgias were the most frequent SAMS (n = 29). Rhabdomyolysis occurred in 4 patients (1 with mitochondrial myopathy and 3 with McArdle disease). Statins unmasked myopathy in 6 of 36 patients. No patient developed immune-mediated necrotizing myopathy. SAMS are generally mild and occur at a frequency similar to the general population in common genetic myopathies, except increased rhabdomyolysis in mitochondrial myopathies and McArdle disease. Statins are generally safe, though not well tolerated, and could be used when closely monitored in several genetic myopathies. In mitochondrial and metabolic myopathies, their use should be approached with caution because of the potential risk of rhabdomyolysis.


  • Ophthalmoparesis as an unusual manifestation of anti-3‑hydroxy-3-methyl-glutaryl-coenzyme A reductase antibody-associated myopathies

    by Brendan Putko, Alan Pestronk, Gregory P. Van Stavern, Cecile L. Phan, Grayson Beecher, Teerin Liewluck


  • Improving Documentation of Impulse Control Disorders at a Movement Disorder Program During the COVID-19 Pandemic

    by Brendan N. Putko, Janis M. Miyasaki

    Background and Objectives Impulse control disorders (ICD) are a group of behaviors in Parkinson disease (PD), (compulsive buying, gambling, binge eating, craving sweets, and hypersexuality) that occur in up to 20% of individuals with PD, sometimes with devastating results. We sought to determine the rate of ICD screening based on 2020 quality measures for PD care by the American Academy of Neurology. Methods We conducted a quality improvement project to document and improve physician ICD screening in a tertiary movement disorder program. Serial medical records were reviewed for 5 weeks before and 13 weeks after an educational session and documentation tool deployments in 2020. Inclusion criteria included the following: idiopathic PD, PD dementia (PDD), or dementia with Lewy bodies (DLB). Individual encounters for 109 patients preintervention and 276 patients postintervention were reviewed. Results There was no difference between the preintervention and postintervention (pre-IG vs post-IG, respectively) in terms of age, male to female ratio, proportion of patients with PD, PDD, or DLB, duration of diagnosis, or levodopa equivalents. There was a shift to increased ICD queries above the median for the study period (28.8%) for 7 consecutive weeks in post-IG. The frequency of ICD diagnosis was not different from pre-IG to post-IG (95% confidence interval, 0–32.6 vs 2.7–13.4%, p = 0.444). Discussion ICD queries immediately after ICD education and dissemination of documentation tools increased. Both preintervention and postintervention groups were similar in demographic and clinical characteristics. This program was instituted at the height of wave 2 of the COVID-19 pandemic in Alberta during staff redeployment and 100% shift to telemedicine ambulatory care. Our results demonstrate that amid a crisis, quality improvement can still be effective with education and provision of tools for clinicians.

  • Open Access

    Bing–Neel Syndrome Mimicking Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis

    by Grayson Beecher, Brendan Nicholas Putko, Amanda Nicole Wagner, Ryan Hung, Cecile Phan, Sanjay Kalra